WAM
REGN icon

WealthTrust Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

WealthTrust Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-706
Closed -$742K – 98
2024
Q3 		$742K Sell
706
-73
-9% -$81.2K 0.55% 45
2024
Q2 		$819K Buy
779
+7
+0.9% +$6.79K 0.6% 45
2024
Q1 		$743K Buy
+772
New +$734K 0.57% 43
2022
Q3 		– Sell
-1,739
Closed -$1.03M – 77
2022
Q2 		$1.03M Buy
+1,739
New +$1.13M 0.97% 31

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

WealthTrust Asset Management's REGN Position: Q4 2024 in Review

WealthTrust Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 706 shares — an estimated $742K sold.

WealthTrust Asset Management first reported a position in REGN in Q2 2022 and held it in 4 quarters. The position peaked at $1.03M in Q2 2022. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • WealthTrust Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • WealthTrust Asset Management sold 706 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $742K.
  • WealthTrust Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • WealthTrust Asset Management's Regeneron Pharmaceuticals position peaked at $1.03M in Q2 2022.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on WealthTrust Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.